Sarepta Therapeutics Net Worth
Sarepta Therapeutics Net Worth Breakdown | SRPT |
Sarepta Therapeutics Net Worth Analysis
Sarepta Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Sarepta Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Sarepta Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Sarepta Therapeutics' net worth analysis. One common approach is to calculate Sarepta Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Sarepta Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Sarepta Therapeutics' net worth. This approach calculates the present value of Sarepta Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Sarepta Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Sarepta Therapeutics' net worth. This involves comparing Sarepta Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Sarepta Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Sarepta Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Sarepta Therapeutics' net worth research are outlined below:
| Sarepta Therapeutics generated a negative expected return over the last 90 days | |
| Sarepta Therapeutics is unlikely to experience financial distress in the next 2 years | |
| Sarepta Therapeutics currently holds about 2.07 B in cash with (205.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 23.61. | |
| Sarepta Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 93.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Sarepta Therapeutics Inc Q4 2024 Earnings Call Highlights Record Revenue Growth and ... |
Sarepta Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Sarepta Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Sarepta Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 7th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Sarepta Therapeutics Target Price Consensus
Sarepta target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Sarepta Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 22 | Strong Buy |
Most Sarepta analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Sarepta stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Sarepta Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationSarepta Therapeutics Target Price Projection
Sarepta Therapeutics' current and average target prices are 106.75 and 184.91, respectively. The current price of Sarepta Therapeutics is the price at which Sarepta Therapeutics is currently trading. On the other hand, Sarepta Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Sarepta Therapeutics Market Quote on 2nd of March 2025
Target Price
Analyst Consensus On Sarepta Therapeutics Target Price
Know Sarepta Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Sarepta Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Sarepta Therapeutics backward and forwards among themselves. Sarepta Therapeutics' institutional investor refers to the entity that pools money to purchase Sarepta Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-12-31 | 1.7 M | Deutsche Bank Ag | 2024-12-31 | 1.7 M | Ubs Group Ag | 2024-12-31 | 1.5 M | Groupama Asset Management | 2024-12-31 | 1.3 M | Casdin Capital, Llc | 2024-12-31 | 1.1 M | Pictet Asset Manangement Sa | 2024-09-30 | 1.1 M | Norges Bank | 2024-12-31 | 1 M | Camber Capital Management Llc | 2024-12-31 | 1000 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 991.7 K | Blackrock Inc | 2024-12-31 | 11.2 M | Vanguard Group Inc | 2024-12-31 | 9.1 M |
Follow Sarepta Therapeutics' market capitalization trends
The company currently falls under 'Large-Cap' category with a current market capitalization of 10.34 B.Market Cap |
|
Project Sarepta Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.06 | 0.06 | |
| Return On Capital Employed | 0.07 | 0.07 | |
| Return On Assets | 0.06 | 0.06 | |
| Return On Equity | 0.15 | 0.16 |
When accessing Sarepta Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Sarepta Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Sarepta Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Sarepta Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Sarepta Therapeutics. Check Sarepta Therapeutics' Beneish M Score to see the likelihood of Sarepta Therapeutics' management manipulating its earnings.
Evaluate Sarepta Therapeutics' management efficiency
Sarepta Therapeutics has return on total asset (ROA) of 0.0377 % which means that it generated a profit of $0.0377 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1971 %, meaning that it created $0.1971 on every $100 dollars invested by stockholders. Sarepta Therapeutics' management efficiency ratios could be used to measure how well Sarepta Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to 0.06 in 2025. Return On Capital Employed is likely to gain to 0.07 in 2025. At this time, Sarepta Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 4.2 B in 2025, whereas Non Current Liabilities Other is likely to drop slightly above 44.9 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 16.07 | 16.87 | |
| Tangible Book Value Per Share | 16.07 | 16.87 | |
| Enterprise Value Over EBITDA | 54.05 | 56.75 | |
| Price Book Value Ratio | 7.57 | 6.75 | |
| Enterprise Value Multiple | 54.05 | 56.75 | |
| Price Fair Value | 7.57 | 6.75 | |
| Enterprise Value | 10.8 B | 11.3 B |
Effective leadership at Sarepta Therapeutics drives its competitive edge in the market. Our analysis focuses on how this translates to financial performance and stock value.
Enterprise Value Revenue 5.447 | Revenue | Quarterly Revenue Growth 0.659 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sarepta Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sarepta Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Sarepta Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Sarepta Therapeutics Corporate Filings
10K | 28th of February 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
8K | 26th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 13th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 29th of November 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Sarepta Therapeutics Earnings Estimation Breakdown
The calculation of Sarepta Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Sarepta Therapeutics is estimated to be 1.7528 with the future projection ranging from a low of -1.58 to a high of 2.84. Please be aware that this consensus of annual earnings estimates for Sarepta Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-1.58 Lowest | Expected EPS | 2.84 Highest |
Sarepta Therapeutics Earnings Projection Consensus
Suppose the current estimates of Sarepta Therapeutics' value are higher than the current market price of the Sarepta Therapeutics stock. In this case, investors may conclude that Sarepta Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Sarepta Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2025 | Current EPS (TTM) | |
| 23 | 16.46% | 1.9 | 1.7528 | 2.34 |
Sarepta Therapeutics Earnings per Share Projection vs Actual
Actual Earning per Share of Sarepta Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Sarepta Therapeutics predict the company's earnings will be in the future. The higher the earnings per share of Sarepta Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Sarepta Therapeutics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Sarepta Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Sarepta Therapeutics should always be considered in relation to other companies to make a more educated investment decision.Sarepta Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Sarepta Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-02-26 | 2024-12-31 | 2.0603 | 1.9 | -0.1603 | 7 | ||
2024-11-06 | 2024-09-30 | -0.13 | 0.34 | 0.47 | 361 | ||
2024-08-07 | 2024-06-30 | 0.01 | 0.07 | 0.06 | 600 | ||
2024-05-01 | 2024-03-31 | -0.07 | 0.37 | 0.44 | 628 | ||
2024-02-28 | 2023-12-31 | 0.01 | 0.47 | 0.46 | 4600 | ||
2023-11-01 | 2023-09-30 | -1.23 | -0.46 | 0.77 | 62 | ||
2023-08-02 | 2023-06-30 | -1.78 | -0.27 | 1.51 | 84 | ||
2023-05-02 | 2023-03-31 | -1.38 | -5.86 | -4.48 | 324 | ||
2023-02-28 | 2022-12-31 | -1.35 | -1.24 | 0.11 | 8 | ||
2022-11-02 | 2022-09-30 | -1.43 | -2.94 | -1.51 | 105 | ||
2022-08-02 | 2022-06-30 | -1.18 | -2.65 | -1.47 | 124 | ||
2022-05-04 | 2022-03-31 | -1.27 | -1.2 | 0.07 | 5 | ||
2022-03-01 | 2021-12-31 | -1.13 | -1.42 | -0.29 | 25 | ||
2021-11-03 | 2021-09-30 | -1.89 | -0.19 | 1.7 | 89 | ||
2021-08-04 | 2021-06-30 | -1.28 | -2.3 | -1.02 | 79 | ||
2021-05-05 | 2021-03-31 | -1.74 | -2.1 | -0.36 | 20 | ||
2021-03-01 | 2020-12-31 | -1.78 | -2.4 | -0.62 | 34 | ||
2020-11-05 | 2020-09-30 | -1.64 | -1.93 | -0.29 | 17 | ||
2020-08-05 | 2020-06-30 | -1.68 | -1.93 | -0.25 | 14 | ||
2020-05-06 | 2020-03-31 | -1.88 | -0.23 | 1.65 | 87 | ||
2020-02-26 | 2019-12-31 | -1.86 | -3.16 | -1.3 | 69 | ||
2019-11-07 | 2019-09-30 | -1.35 | -1.7 | -0.35 | 25 | ||
2019-08-07 | 2019-06-30 | -1.37 | -1.39 | -0.02 | 1 | ||
2019-05-08 | 2019-03-31 | -1.7 | -1.07 | 0.63 | 37 | ||
2019-02-27 | 2018-12-31 | -1.02 | -2.05 | -1.03 | 100 | ||
2018-10-24 | 2018-09-30 | -0.81 | -1.15 | -0.34 | 41 | ||
2018-08-08 | 2018-06-30 | -0.89 | -1.67 | -0.78 | 87 | ||
2018-05-03 | 2018-03-31 | -0.3 | -0.55 | -0.25 | 83 | ||
2018-03-01 | 2017-12-31 | -0.32 | -0.37 | -0.05 | 15 | ||
2017-10-25 | 2017-09-30 | -0.85 | -0.76 | 0.09 | 10 | ||
2017-07-19 | 2017-06-30 | -0.91 | -0.46 | 0.45 | 49 | ||
2017-04-27 | 2017-03-31 | -0.32 | -0.71 | -0.39 | 121 | ||
2017-02-28 | 2016-12-31 | -1.33 | -0.87 | 0.46 | 34 | ||
2016-10-27 | 2016-09-30 | -1.32 | -1.18 | 0.14 | 10 | ||
2016-07-19 | 2016-06-30 | -1.19 | -1.35 | -0.16 | 13 | ||
2016-05-05 | 2016-03-31 | -1.28 | -1.31 | -0.03 | 2 | ||
2016-02-25 | 2015-12-31 | -1.18 | -1.44 | -0.26 | 22 | ||
2015-11-05 | 2015-09-30 | -1.18 | -1.25 | -0.07 | 5 | ||
2015-08-06 | 2015-06-30 | -1.21 | -1.01 | 0.2 | 16 | ||
2015-05-07 | 2015-03-31 | -1 | -1.49 | -0.49 | 49 | ||
2015-02-26 | 2014-12-31 | -0.82 | -1.08 | -0.26 | 31 | ||
2014-11-06 | 2014-09-30 | -0.96 | -0.71 | 0.25 | 26 | ||
2014-08-07 | 2014-06-30 | -0.76 | -0.85 | -0.09 | 11 | ||
2014-05-08 | 2014-03-31 | -0.8 | -0.75 | 0.05 | 6 | ||
2014-02-27 | 2013-12-31 | -0.69 | -0.23 | 0.46 | 66 | ||
2013-11-12 | 2013-09-30 | -0.65 | -1.24 | -0.59 | 90 | ||
2013-08-08 | 2013-06-30 | -0.61 | -0.6 | 0.01 | 1 | ||
2013-05-09 | 2013-03-31 | -0.62 | -1.32 | -0.7 | 112 | ||
2013-03-07 | 2012-12-31 | -0.29 | -2.36 | -2.07 | 713 | ||
2012-11-07 | 2012-09-30 | -0.28 | -0.3 | -0.02 | 7 | ||
2012-08-07 | 2012-06-30 | -0.21 | 0.35 | 0.56 | 266 | ||
2012-05-10 | 2012-03-31 | -0.44 | -0.78 | -0.34 | 77 | ||
2012-03-01 | 2011-12-31 | -0.33 | -0.06 | 0.27 | 81 | ||
2011-11-03 | 2011-09-30 | -0.35 | -0.18 | 0.17 | 48 | ||
2011-08-04 | 2011-06-30 | -0.4 | 0.06 | 0.46 | 115 | ||
2011-05-05 | 2011-03-31 | -0.19 | 0.12 | 0.31 | 163 | ||
2011-03-10 | 2010-12-31 | -0.42 | -0.42 | 0.0 | 0 | ||
2010-11-09 | 2010-09-30 | -0.36 | -0.42 | -0.06 | 16 | ||
2010-08-09 | 2010-06-30 | -0.3 | -0.9 | -0.6 | 200 | ||
2010-05-10 | 2010-03-31 | -0.27 | -0.06 | 0.21 | 77 | ||
2010-03-16 | 2009-12-31 | -0.27 | 0.18 | 0.45 | 166 | ||
2009-11-09 | 2009-09-30 | -0.39 | -0.48 | -0.09 | 23 | ||
2009-08-10 | 2009-06-30 | -0.12 | -1.38 | -1.26 | 1050 | ||
2009-05-11 | 2009-03-31 | -0.27 | -0.06 | 0.21 | 77 | ||
2009-03-10 | 2008-12-31 | -0.36 | -0.06 | 0.3 | 83 | ||
2008-11-10 | 2008-09-30 | -0.39 | -0.48 | -0.09 | 23 | ||
2008-08-11 | 2008-06-30 | -0.45 | -0.12 | 0.33 | 73 | ||
2008-05-12 | 2008-03-31 | -0.45 | -1.38 | -0.93 | 206 | ||
2008-03-12 | 2007-12-31 | -0.48 | -0.42 | 0.06 | 12 | ||
2007-11-06 | 2007-09-30 | -0.72 | -0.78 | -0.06 | 8 | ||
2007-08-08 | 2007-06-30 | -0.75 | -0.96 | -0.21 | 28 | ||
2007-05-09 | 2007-03-31 | -0.78 | -1.08 | -0.3 | 38 | ||
2007-03-15 | 2006-12-31 | -0.84 | -0.96 | -0.12 | 14 | ||
2006-11-08 | 2006-09-30 | -0.84 | -0.78 | 0.06 | 7 | ||
2006-08-08 | 2006-06-30 | -0.66 | -0.78 | -0.12 | 18 | ||
2006-05-05 | 2006-03-31 | -0.36 | -1.08 | -0.72 | 200 | ||
2006-03-08 | 2005-12-31 | -0.63 | -0.6 | 0.03 | 4 | ||
2005-11-04 | 2005-09-30 | -0.76 | -0.24 | 0.52 | 68 | ||
2005-08-08 | 2005-06-30 | -0.7 | -0.66 | 0.04 | 5 | ||
2005-05-09 | 2005-03-31 | -0.72 | -0.78 | -0.06 | 8 | ||
2005-03-08 | 2004-12-31 | -0.87 | -0.84 | 0.03 | 3 | ||
2004-11-04 | 2004-09-30 | -0.84 | -0.84 | 0.0 | 0 | ||
2004-08-05 | 2004-06-30 | -1.23 | -1.2 | 0.03 | 2 | ||
2004-05-05 | 2004-03-31 | -0.84 | -1.26 | -0.42 | 50 | ||
2004-03-09 | 2003-12-31 | -0.88 | -1.26 | -0.38 | 43 | ||
2003-11-04 | 2003-09-30 | -0.8 | -0.9 | -0.1 | 12 | ||
2003-08-05 | 2003-06-30 | -0.72 | -0.72 | 0.0 | 0 | ||
2003-05-06 | 2003-03-31 | -0.99 | -0.78 | 0.21 | 21 | ||
2003-03-11 | 2002-12-31 | -1.29 | -0.9 | 0.39 | 30 | ||
2002-08-06 | 2002-06-30 | -1.08 | -1.8 | -0.72 | 66 | ||
2002-05-07 | 2002-03-31 | -1.02 | -1.98 | -0.96 | 94 | ||
2002-03-12 | 2001-12-31 | -1.14 | -1.2 | -0.06 | 5 |
Sarepta Therapeutics Corporate Management
| Ryan JD | General VP | Profile | |
| Will Tilton | Head VP | Profile | |
| Joseph Bratica | Controller VP | Profile | |
| William Ciambrone | Ex Operations | Profile | |
| Dallan Murray | Executive Officer | Profile |
Additional Tools for Sarepta Stock Analysis
When running Sarepta Therapeutics' price analysis, check to measure Sarepta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sarepta Therapeutics is operating at the current time. Most of Sarepta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sarepta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sarepta Therapeutics' price. Additionally, you may evaluate how the addition of Sarepta Therapeutics to your portfolios can decrease your overall portfolio volatility.